KR20240082364A - 인터루킨-2 돌연변이 및 이의 융합 단백질 - Google Patents

인터루킨-2 돌연변이 및 이의 융합 단백질 Download PDF

Info

Publication number
KR20240082364A
KR20240082364A KR1020247013147A KR20247013147A KR20240082364A KR 20240082364 A KR20240082364 A KR 20240082364A KR 1020247013147 A KR1020247013147 A KR 1020247013147A KR 20247013147 A KR20247013147 A KR 20247013147A KR 20240082364 A KR20240082364 A KR 20240082364A
Authority
KR
South Korea
Prior art keywords
amino acid
antibody
cells
seq
acid sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020247013147A
Other languages
English (en)
Korean (ko)
Inventor
카이지에 허
펭겐 푸
웨이웨이 우
슈아이시앙 조우
지안 구안
Original Assignee
포트비타 바이오로직스 (싱가포르) 피티이. 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 포트비타 바이오로직스 (싱가포르) 피티이. 리미티드 filed Critical 포트비타 바이오로직스 (싱가포르) 피티이. 리미티드
Publication of KR20240082364A publication Critical patent/KR20240082364A/ko
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/55—IL-2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
KR1020247013147A 2021-09-22 2022-09-21 인터루킨-2 돌연변이 및 이의 융합 단백질 Pending KR20240082364A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN202111110032 2021-09-22
CN202111110032.3 2021-09-22
PCT/CN2022/120265 WO2023045977A1 (zh) 2021-09-22 2022-09-21 白介素2突变体以及其融合蛋白

Publications (1)

Publication Number Publication Date
KR20240082364A true KR20240082364A (ko) 2024-06-10

Family

ID=85720093

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020247013147A Pending KR20240082364A (ko) 2021-09-22 2022-09-21 인터루킨-2 돌연변이 및 이의 융합 단백질

Country Status (14)

Country Link
US (2) US20240391973A1 (https=)
EP (1) EP4406965A4 (https=)
JP (1) JP2024534545A (https=)
KR (1) KR20240082364A (https=)
CN (1) CN118119635A (https=)
AU (2) AU2022350407B2 (https=)
CA (1) CA3233075A1 (https=)
CL (1) CL2024000834A1 (https=)
CO (1) CO2024004910A2 (https=)
IL (1) IL311643A (https=)
MX (1) MX2024003535A (https=)
PE (1) PE20241994A1 (https=)
TW (1) TWI858393B (https=)
WO (1) WO2023045977A1 (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3854805A4 (en) 2018-09-21 2022-08-24 Innovent Biologics (Suzhou) Co., Ltd. NOVEL INTERLEUKIN 2 AND ITS USE
JP2023518434A (ja) * 2020-03-19 2023-05-01 イノベント バイオロジクス（スーチョウ）カンパニー，リミティド インターロイキン２変異体およびその使用
WO2025007037A1 (en) * 2023-06-28 2025-01-02 Dragonfly Therapeutics, Inc. Variant il-2 proteins
WO2025031434A1 (zh) * 2023-08-08 2025-02-13 北京志道生物科技有限公司 经修饰的细胞因子与cd40激动剂的联用组合物及其抗肿瘤用途
WO2025140535A1 (zh) * 2023-12-28 2025-07-03 福佑泰生物制药（新加坡）公司 Pd-1/il-2r双特异性抗体融合蛋白及其用途和使用方法
CN118373896B (zh) * 2024-04-19 2025-07-29 上海科棋药业科技有限公司 抗pd-1抗体与il-2突变体的双功能融合蛋白
WO2025252212A1 (zh) * 2024-06-07 2025-12-11 福佑泰生物制药公司 抗pd-1抗体与细胞因子il-12突变蛋白的免疫缀合物以及其应用
WO2026012466A1 (en) * 2024-07-12 2026-01-15 Vibrant Pharma Limited Interleukin-2 muteins and uses thereof
CN118546233B (zh) * 2024-07-30 2024-10-18 成都微芯新域生物技术有限公司 白介素-21突变体及其应用
CN121293311A (zh) * 2025-08-01 2026-01-09 合肥天港免疫药物有限公司 Il-2变体及其应用

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4518584A (en) 1983-04-15 1985-05-21 Cetus Corporation Human recombinant interleukin-2 muteins
NZ234674A (en) * 1989-08-02 1992-02-25 Seragen Inc Mutant interleukin-2,dna encoding it, host cells, cytotoxic and toxin-mutant il-2 conjugates
DZ2788A1 (fr) 1998-05-15 2003-12-01 Bayer Ag Agonistes et antagonistes selectifs à IL-2.
US6955807B1 (en) * 1998-05-15 2005-10-18 Bayer Pharmaceuticals Corporation IL-2 selective agonists and antagonists
WO2017024465A1 (en) * 2015-08-10 2017-02-16 Innovent Biologics (Suzhou) Co., Ltd. Pd-1 antibodies
MY201482A (en) 2017-04-03 2024-02-26 Hoffmann La Roche Immunoconjugates of an anti-pd-1 antibody with a mutant il-2 or with il-15
JP7148539B2 (ja) * 2017-04-03 2022-10-05 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト 免疫抱合体
IL275426B2 (en) * 2017-12-19 2025-03-01 Xencor Inc Engineered il-2 fc fusion proteins
US12280118B2 (en) * 2017-12-27 2025-04-22 Kyowa Kirin Co., Ltd. IL-2 variant
EP3854805A4 (en) * 2018-09-21 2022-08-24 Innovent Biologics (Suzhou) Co., Ltd. NOVEL INTERLEUKIN 2 AND ITS USE
WO2020252418A2 (en) * 2019-06-14 2020-12-17 Cugene, Inc. Novel interleukin-2 variants for the treatment of cancer
WO2020252421A2 (en) * 2019-06-14 2020-12-17 Cugene, Inc. Novel interleukin-2 variants and bifunctional fusion molecules thereof
JP2023518434A (ja) * 2020-03-19 2023-05-01 イノベント バイオロジクス（スーチョウ）カンパニー，リミティド インターロイキン２変異体およびその使用
AU2021237518B2 (en) * 2020-03-19 2024-08-15 Fortvita Biologics (Singapore) Pte.Ltd. Interleukin-2 mutant and use thereof

Also Published As

Publication number Publication date
PE20241994A1 (es) 2024-09-27
AU2022350407A1 (en) 2024-05-02
EP4406965A1 (en) 2024-07-31
WO2023045977A1 (zh) 2023-03-30
AU2022350407B2 (en) 2025-09-04
EP4406965A4 (en) 2025-12-17
JP2024534545A (ja) 2024-09-20
CN118119635A (zh) 2024-05-31
IL311643A (en) 2024-05-01
CA3233075A1 (en) 2023-03-30
AU2025275202A1 (en) 2026-02-19
TWI858393B (zh) 2024-10-11
CL2024000834A1 (es) 2024-09-06
US20240391973A1 (en) 2024-11-28
CO2024004910A2 (es) 2024-07-08
TW202320862A (zh) 2023-06-01
MX2024003535A (es) 2024-05-07
US20260053898A1 (en) 2026-02-26

Similar Documents

Publication Publication Date Title
TWI858393B (zh) 介白素２突變體以及其融合蛋白
JP7662516B2 (ja) Ｐｄ－１標的化ｉｌ－１５／ｉｌ－１５ｒアルファｆｃ融合タンパク質およびその組み合わせ療法での使用
TWI826880B (zh) 白細胞介素２１突變體以及其用途
AU2018393424B2 (en) Triabody, preparation method and use thereof
CN110305210B (zh) 新型抗体分子、其制备方法及其用途
CN112867734A (zh) 包含IL-15/IL-15Ra Fc融合蛋白和PD-1抗原结合结构域的靶向PD-1的异源二聚体融合蛋白及其用途
TW201806972A (zh) 雙特異性結合蛋白
JP2023159380A (ja) ＰＤ－１とＴＧＦ－ｂｅｔａを標的とした四価二重特異性抗体、その製造方法および用途
TW202235104A (zh) 雙功能分子
WO2023052846A2 (en) Immunocytokine containing il-21r mutein
KR20230070238A (ko) 4-1bb를 표적으로 하는 단일 도메인 항체, 이의 융합 단백질, 이의 약제학적 조성물 및 용도
CN117062840A (zh) 靶向bcma的多特异性抗体
EP4587046A1 (en) Mage-a4 peptide dual t cell engagers
CN119894934A (zh) 结合lilrb4和cd3的抗体及其用途
CN121646609A (zh) Tnf超家族成员免疫细胞因子及其用途
US12545732B2 (en) PD-1 antigen-binding protein and use thereof
US20250282874A1 (en) Bifunctional protein, and preparation thereof and use thereof
CN121086061A (zh) 抗pd-1抗体与细胞因子il-12突变蛋白的免疫缀合物以及其应用
IL325137A (en) Preparation and use of a trispecific antibody against gprc5d/bcma/cd3
EA051272B1 (ru) Мультиспецифическое антитело, нацеленное на bcma
EA045980B1 (ru) Антитела против рецептора полиовируса (pvr) и их применение

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000